Different generations of the immunotoxins could be targeting cancerous cells by interactions between ligand and cell surface specific antigens. Therefore, identification and characterization of these types of ligands and corresponding antigens, which are constantly growing, would be a milestone step to design a novel generation of immunotoxins. Bearing in mind, a profile of cell surface specific antigens was collected, and then the expressions of them were measured via in silico program on several normal and cancerous tissues. Corresponding ligands of the selected antigens were then investigated by String, and validated through docking process. On the other hand, structural and functional characteristics as well as posttranslational modifications of the ligands were examined. Finally, amino acids of ligands that are involved in interaction to antigens were determined. The results of this study led to introducing several antigens including Gp75, MAGEA3, APCs, PSA, and MSLN with high expression on the surface of some cancerous cells. Moreover, this investigation revealed HLA-A, ALDH3A2, MLANA, AR, CALB2, SILV, CALU, and GAGE1 as ligands with high affinity to one or more selected antigens. Meanwhile, ligand miniaturization led to design a new generation of ligands with 30 amino acid in length and limited in post-translational modification.Taken together, these results introduced a series of cell surface specific antigens which can use for cancer diagnosis, and provide a numerous of candidate ligands to develop a new generation of immunotoxins for targeting breast, prostate, ovary and melanoma cancer cells. (5, 6). So, ideally anticancer agents should act exclusively against tumor cells; without side effects on the human body (7) . Accordingly, in the new era of 'precision' cancer medicine, new drug development has shifted from cytotoxic chemotherapy to molecularly targeted agents. In this regard, a growing number of monoclonal antibodies and immunotoxins have been approved for the treatment of malignancies (8) (9) (10) . Immunotoxins that are hybrid proteins from targeting and killing moieties components must remain intact while in the systemic circulation, but it must disassemble inside the target cell in order to release the toxin (10, 11) . These therapeutic agents takes advantage of some special properties of cancer cells, especially cell-surface specifics antigens as targets to eliminate the cancer cells in that they are sparing on the normal cells (12) . However, the clinical development of immunotoxins suffering by a variety of problems, including poor antigen specificity, low cytotoxicity, nonspecific toxicities, immunogenicity, and production difficulties, which some of them considered in this study based on in silico simulation.
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MATERIALS AND METHODS
In order to profile comprehensive ligands with targeting capacity of the cancerous cell surface specific antigens, at the first step these antigens were gathered. Subsequently, while their expressions of detected antigens were determined by literature, confirming via protein atlas program.
On the other hand, the nucleotide sequences and corresponding proteins of the ligands and matching antigens were retrieved from NCBI, Uniprot, and EMBL. Moreover, 3D structure of the selected antigens were retrieved or prepared via PDB, SWISS -MODEL and or by Modeller program. Furthermore, corresponding ligands of the selected antigens were then determined by data survey and using of the String program. The protein sequences of the selected ligands were then analyzed via PTM tools assay. Finally, the binding affinity of the ligands to antigens were performed using Hex and Cluspro programs and then visualized their interaction via Pymol software. Moreover, in silico expression as well as interaction assays were carried out in at least triplicate, and the generated data were expressed as mean standard deviation. One-way analysis of variance (ANOVA) was used to analyze the antigen expression on different tissues. ANOVA was done by a Tukey post hoc test. Statistical significance was considered at P < 0.05. All statistical analyses were carried out with SPSS 16.0 (SPSS Inc., Chicago, IL, USA).
RESULT
The results of ligands profiling led to disclosure a numerous of ligands with capacity to targeting cancerous cell surface specific antigens ( Table 1) . As showed in this table, some of these ligands could be targeting several antigens of various malignant tissues such as HLA-A with 4 targets in Breast, Ovarian, Prostate, Melanoma, Skin and Prostate cancers that are including MSLN, SILV, MAGE1 and MAGE3 antigens. Subsequently in order to evaluate the quality of ligand interaction to corresponding antigens, binding affinity as well as situation of interaction were determined ( Figure 1 ). As showed in this figure HLA-A with binding affinity domain to MSLN, SILV, MAGE1 and MAGE3 antigens showed several amino acid in each interaction which could be applied in ligand designing. Targets  Ligand  Targets  Ligand  Targets  Ligand  Targets  Ligand   HSP70  HSPBP1  CTGF  FN1  APCs  FCGR2A  CTGF  BMP7  SILV  MLANA  CTGF  VEGFA  APCs  CALU  FOLH1  FLNA  SILV  HLA-A  CTGF  BMP4  KLK3  AR  FOLH1  Arc40  HSP70  TP53  HER2  EGF  KLK3  SERPINA1  FOLH1  KLK3  HSP70  PARK2  HER2  SHC1  KLK3  SERPINA5  EphB2  EFNB2  HSP70  BAG3  MAGE1  HLA-A  KLK3  A2M  EphB2  EFNB1  HSP70  STIP1  MAGE3  HLA-A  MSLN  MUC16  EphB2  RASA1  HSP70  STUB1  HER2  GRB7  MSLN  HLA-DR15  EphB2  SRC  HSP70  HSP90AA1  HER2  SRC  MSLN  HLA-A  EphB2  TIAM1  HSP70  HSF1  HER2  HSP90AA1  MUC16  MSLN  EphB2  ITSN1  HSP70  BAG1  HER2  ERBB2IP  MUC16  LGALS1  EphB2  EFNA5  SSTR2A  SST  HER2  GRB2  FAP  PLAUR  EphB2  EFNB3  SSTR2A  SHANK1  HER2  ERBB3  FAP  DPP4  CEA  SELE  SSTR2A  SSTR3  HER2  EGFR  HSP70  HIF1A  CEA  HNRNPM  HSP70  HIF1A  HER2  UBC   Table 1 Following to assessments the circumstances of the interaction, energy of binding affinity of the ligands to corresponding antigens were investigated ( Figure  2 ). This analysis led to disclosure results that were contradictory and or in line of the scoring of the interaction in some cases. However, as showed in this figure among selected ligands MLANA with the lowest energy have more affinity to corresponding antigen, SILV, which propounded as a suitable candidate in immunotoxin designing. Meanwhile, ligands miniaturizations led to achieving a series of small ligands with 30 amino acid in length (data not shown) which ought to more analysis. Moreover, post-translation modifications (PTM) of the selected ligands were then assessment ( Figure 3 and Table 2 ). As showed in the figure and confirmed in the table 2, among these ligands MLANA have lowest sites for PTM that advocated candidacy of this ligand for immunotoxin designing.
On the other hand, in silico expression assays of the corresponding antigens of the selected ligands were investigated. This analysis led to reveal significant results, so that the most of them which were reported previously as specific cancerous antigens showed expression at various tissues on the normal and malignant condition ( Figure 4 ). As showed in this figure, MSLN as a tumor specific antigen for lung cancers (13) could be expressed in various normal and cancerous tissues at different level . 
